Represented Gilead Sciences in antitrust class actions brought by direct and indirect purchasers of HIV drugs. After a six-week trial, the jury returned a complete defense verdict, rejecting plaintiffs’ pay-for-delay claims, for which they sought over $10 billion in compensatory and treble damages. See “How A 3-Firm 'Joint Effort' Beat A $3.6B Pharma Antitrust Suit” Law360, July 5, 2023.
Represented Juul Labs, Inc. in multi-jurisdiction litigation involving product liability, sales, marketing, and design claims.
